Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp30805_8k.htm |
Exhibit 99.01
|
Press Release
|
 |
|
www.shire.com
|
Block listing six monthly return
May 23, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY)
|
Name of applicant:
|
Shire plc
|
|||
|
Name of scheme:
|
2000 Executive Share Option Scheme
|
|||
|
Period of return:
|
From:
|
November 23, 2011
|
To:
|
May 22, 2012
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
3,548,772
|
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
Nil
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
|
65,091
|
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
|
3,483,681
|
|||
|
Name of applicant:
|
Shire plc
|
|||
|
Name of scheme:
|
Shire Sharesave Scheme
|
|||
|
Period of return:
|
From:
|
November 23, 2011
|
To:
|
May 22, 2012
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
5,392
|
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
Nil
|
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
|
Nil
|
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
|
5,392
|
|||
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
|
Name of contact:
|
Tony Guthrie, Deputy Company Secretary
|
|
Address of contact:
|
Hampshire International Business Park
Basingstoke, Hampshire, RG24 8EP
|
|
Telephone number of contact:
|
01256 894746
|
For further information please contact:
|
Investor Relations
|
Eric Rojas (erojas@shire.com)
|
+1 781 482 0999
|
|
Sarah Elton-Farr (seltonfarr@shire.com)
|
+44 1256 894157
|
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.